General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-10 | 2024-03 | -3.59 | -2.02 | 1.57 | 43.73% |
2024-03-22 | 2023-12 | -3 | N/A | N/A | N/A |
2023-11-13 | 2023-09 | -3.15 | -2.85 | 0.3 | 9.52% |
2023-08-11 | 2023-06 | -4.2 | -3 | 1.2 | 28.57% |
2023-05-11 | 2023-03 | -3.75 | -4.2 | -0.45 | -12.00% |
2023-03-22 | 2022-12 | -4.2 | -3.6 | 0.6 | 14.29% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-04-17 | Roth MKM | Upgrade | Buy | |
2023-03-23 | Oppenheimer | Upgrade | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-12-25 | FOSTER JONATHAN P. | Chief Financial Officer | 80.56K | Purchase |
2023-12-25 | GEORGE ROBERT E | Director | 14.66K | Purchase |
2023-12-25 | KLEMP WALTER V | Chief Executive Officer | 680.88K | Purchase |
2017-05-04 | NORTHCUT JACQUELINE | Director | 1000 | Purchase |
2023-06-19 | PICKER DONALD H | Officer | 90.01K | Conversion of Exercise of derivative security |
2017-08-15 | PRIEBE WALDEMAR PH.D. | Beneficial Owner of more than 10% of a Class of Security | 2.78M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.08M | 625.17K | 3.62% |
2023-06-29 | Sio Capital Management, LLC | 303.39K | 175.60K | 1.02% |
2023-06-29 | Geode Capital Management, LLC | 246.45K | 142.65K | 0.83% |
2023-06-29 | Blackrock Inc. | 196.20K | 113.56K | 0.66% |
2023-06-29 | Renaissance Technologies, LLC | 127.40K | 73.74K | 0.43% |
2023-06-29 | Squarepoint Ops LLC | 77.24K | 44.71K | 0.26% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 616.11K | 356.60K | 2.07% |
2023-06-29 | Vanguard Extended Market Index Fund | 454.71K | 263.18K | 1.53% |
2023-05-30 | Fidelity Extended Market Index Fund | 141.91K | 89.90K | 0.48% |
2023-05-30 | Fidelity Series Total Market Index Fund | 33.89K | 21.47K | 0.11% |
2023-05-30 | Fidelity Total Market Index Fund | 30.82K | 19.52K | 0.10% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 15.56K | 9.86K | 0.05% |
Split | Date |
---|---|
1 : 15 | 2024-03-22 |
1 : 6 | 2021-02-01 |
Omg 5$ today get in now it gona pop in an hour
This a flush
$TNXP the cheapest CoVid 19 vaccine will run tomorrow at $3 Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. That’s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
Put in the ask 2.50$ ao it can be boost
Tomorrow marks week 6 in the schedule the CEO gave on 4/16 saying he will update in 4-8 weeks-that’s all you need to know to connect the dots.
Thursday marks week 5 of 4-6weeks in MBRX expected results from their 4/16 conf call statement re Covid-19. I think this is the connection to the trading halt and the data they claim they need to see. I’m in this for cancer indications so Covid is mere frosting on the cake if it works!
This is going to be a Howard Hughes type hearing, contracts like a lot of others. We will see.
Smart money coming in now.
It’s worth $2 to see it into pha 2 trial. Presentation makes a lot of sense. We’ll most likely have Remdesivir to bridge gap in meantime so we can get back to work. Like what I see.
Zacks rank strong buy 2 hours before im hold
Irregular bid ask
$TNXP has huge update. Buy buy hurry
$MBRX Great setup, in at 0.47
Nothing to do with Mbrx
Mbrx: Again sumaera useless info
Mbrx : again Sareena useless info